François Begon - English to French translator. Translation services in Medical (general) - Professor of medicine, MD, Medicine, Medical, English to French, Translation, Translator, Freelance, Editing, Proofreading, Review, subject matter expert, Freelancer, Pharmaceuticals, Cardiology, Oncology, Diabetes, Gastroenterology, Nephrology, Haematology, Immunology, AIDS, Endocrinology, Infectious disease, Neurology, Urology, Psychiatry, Aesthetic, Health care, Health, Trials, Medical Instruments, Medical Devices, Prostheses, Imaging, Clinical Lab, Biotech, Biochemistry, Molecular Biology, Statistics, Advertising, Marketing, Environment, Biology, Device, Instrument, prosthesis, Safety, Lab

Dynamic content (javascript) disabled in this profile. FAQ

Working languages:

English to French

François Begon
Professor of medicine, Translator Editor

Paris, Ile-De-France, France

Local time: 03:46 CET (GMT+1)

Native in: French

Send email

Feedback from
clients and colleagues
on Willingness to Work Again

3 positive reviews

(1 unidentified)

Your feedback

Rate service provider

MD & MSc. and Full Professor of Medicine: Translator/Editor

Freelance translator and/or interpreter,

Verified site user

This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.

This person is not affiliated with any business or Blue Board record at ProZ.com.

Translation, Editing/proofreading, Website localization, MT post-editing, Desktop publishing

Specializes in:
Medical (general)	Medical: Pharmaceuticals
Medical: Instruments	Medical: Cardiology
Biology (-tech,-chem,micro-)	Medical: Health Care
Psychology

English to French - Rates: 0.09 - 0.10 USD per word / 30 - 36 USD per hour

Euro (eur)

PRO-level points: 2335, Questions answered: 2156, Questions asked: 19

Skrill, Check, Money order

Sample translations submitted: 4

English to French: Journal Watch Gastro December 2005 Detailed field: Medical (general)
Source text - English Slow Rate of Disease Progression in HCV-Positive Women Most data on the natural history of hepatitis C virus (HCV) infection are retrospective and suggest that progression to cirrhosis occurs during 20 to 30 years. In this prospective study, researchers reported 25-year outcomes in a cohort of women in East Germany who acquired HCV infection from a single-source outbreak of contaminated anti-D immunoglobulin in 1978 and 1979. Researchers reexamined 1980 women from 15 medical centers (70% of the initial cohort). Mean age at infection was 24; 9.7% of women were obese, and 2.6% had diabetes. Only 3% drank more that 40 g of alcohol daily, and 42% did not drink alcohol at all. After 25 years, 62% of patients complained of constitutional symptoms, such as headaches, myalgias or arthralgias, and fatigue. Overall, 54% had cleared the virus (48% sponta-neously and 6% in response to interferon). Only 9 patients (0.5%) had developed overt cirrhosis, 30 patients (1.5%) had developed advanced fibrosis, and 1 patient had developed hepatocellular carcinoma. Of the 10 patients who had died of HCV-related complications, half had comorbidities (e.g., alcohol abuse). The rate of disease progression increased slightly between the 20-year and the 25-year follow-up evaluations: During these last 5 years, six women developed cirrhosis, and nine developed advanced fibrosis.	Translation - French Évolution lente de l’infection par le VHC chez la femme La plupart des données sur l’évolution naturelle des infections par le virus de l’hépatite C (VHC) sont rétrospectives et semblent indiquer que l’évolution vers la cirrhose se fait sur une durée de 20 à 30 ans. Dans cette étude prospective, les chercheurs rapportent les résultats à 25 ans d’une cohorte de femmes d’ex-Allemagne de l’Est ayant acquis une infection par le VHC par une source unique d’immunoglobuline anti D contaminée en 1978 et 1979. Les chercheurs ont réexaminé 1 980 femmes issues de 15 établissements (soit 70% de la cohorte initiale). L’âge moyen lors de l’infection était de 24 ans; 9,7% de femmes étaient obèses et 2,6% souffraient de diabète. Seulement 3% d’entre elles buvaient plus de 40 g d’alcool par jour et 42% ne buvaient pas du tout d’alcool. Après 25 ans d’évolution, 62% des patientes se plaignaient de symptômes fonctionnels comme des céphalées, des myalgies ou arthralgies et de la fatigue. Globalement, 54% avaient éliminé le virus (48% spontanément et 6% en réponse à un traitement par interféron). Seules 9 patientes (0,5%) avaient développé une cirrhose évidente, 30 patientes (1,5%) une fibrose avancée et une, un carcinome hépatocellulaire. Sur les 10 patientes décédées de complications en rapport avec l’infection par le VHC, la moitié présentaient des comorbidités (p. ex., abus d’alcool). Le taux d’évolution de la maladie a légèrement augmenté entre le suivi à 20 ans et le suivi à 25 ans. Au cours de ces 5 dernières années, six femmes ont en effet développé une cirrhose et neuf une fibrose avancée.
English to French: Altor acquires PIAB Detailed field: Advertising / Public Relations
Source text - English Altor acquires PIAB and plans for expansion Leading industrial vacuum company poised for significant growth Altor Fund II, part of Altor Equity Partners AB, has signed an agreement to acquire PIAB Invest AB, a global leader in industrial vacuum technology. As part of an agreement with the Tell family, Altor plans to grow PIAB significantly over the next coming years, further building upon the company’s reputation for providing technical innovation and customer value. Jacob Tell, Chief Executive Officer and Peter Tell, Director of Technologies will remain as both owners and executive management of PIAB. “As a result of the acquisition, PIAB will have access to the capital and industrial expertise required to take the company to the next level. I see ample opportunities to grow and I look forward to working together with PIAB’s global management team to further strengthen our offering to our customers around the world” says Jacob Tell, CEO of PIAB. Based in Täby Sweden, PIAB provides efficient, reliable vacuum technology for OEMs and end-users in a variety of industries such as packaging, automotive, graphic, general industrial and conveying. PIAB’s vacuum solutions are based on COAX® technology, which allows for the design of an extremely flexible, modular and energy efficient vacuum system. “PIAB has developed a technology base that no one in the world can match in terms of productivity improvements and energy savings for its customers. We believe that the growth potential for PIAB is substantial” says Bengt Maunsbach, Director at Altor Equity Partners AB. First founded by Sven Tell in 1951, PIAB has grown significantly to become a global leader in industrial vacuum technology, with a focus on providing innovative solutions that improve the productivity and working environment of vacuum users around the world. Peter Tell founded PIAB’s vacuum division in 1968 after inventing the world’s first vacuum pump based on the multistage ejector technology. PIAB has since then continued to lead the technology development with, for instance, the invention of COAX® technology—a vacuum system using COAX® technology can increase speeds of industrial automation processes by up to 40%, provide three times more vacuum flow, and consume much less compressed air than conventional vacuum technologies. ”The Tell family has developed PIAB into an impressive company with industry leading products. Based on that platform we plan to drive global consolidation and develop PIAB into an important player in the industrial automation sector” says Harald Mix, Partner at Altor Equity Partners AB. PIAB Sweden AB, producer of force measurement equipment, will remain with the Tell family and change its name to Xerex AB.	Translation - French Altor fait l’acquisition de PIAB et prévoit un développement La principale entreprise du vide industriel s’apprête à connaître une croissance significative Le fonds Altor II, qui fait partie de Altor Equity Partners AB, a signé un accord au terme duquel il fait l’acquisition de PIAB Invest AB, un leader mondial dans la technologie du vide industriel. Dans l’une des clauses de l’accord passé avec la famille Tell, Altor prévoit de développer PIAB de façon importante dans les années qui viennent, en s’appuyant sur la réputation de la société pour son innovation technique et sa gestion de la valeur client. Jacob Tell, Directeur Général, et Peter Tell, Directeur des technologies, resteront à la fois comme actionnaires et comme membres de la direction générale de PIAB. “Suite à cette acquisition, PIAB disposera des capitaux et de l’expertise industrielle nécessaires pour hisser la société à un niveau supérieur. J’entrevois de grandes opportunités pour notre développement et j’ai hâte de travailler avec l’équipe de la direction mondiale de PIAB pour renforcer notre offre aux clients dans le monde” a déclaré Jacob Tell, Directeur Général de PIAB. Situé à Täby en Suède, PIAB propose une technologie du vide efficace et fiable en OEM et aux utilisateurs finaux appartenant à un large spectre d’industries, tels que l’emballage, l’automobile, le graphisme, l’industrie générale et le transport. Les solutions de vide de PIAB sont basées sur la technologie COAX®, qui permet de concevoir des systèmes de vide extrêmement flexibles, modulaires et efficients au plan énergétique. “PIAB a développé une base de technologie que personne au monde ne peut égaler pour ce qui est des améliorations de productivité et des économies d’énergie pour les clients. Nous estimons que le potentiel de croissance de PIAB est important” fait remarquer Bengt Maunsbach, Directeur à Altor Equity Partners AB. Initialement fondé par Sven Tell en 1951, PIAB s’est développé considérablement pour devenir un leader mondial de la technologie du vide industriel, avec comme point fort une offre de solutions innovantes améliorant la productivité et l’environnement du travail pour les utilisateurs de vide dans le monde. Peter Tell a créé la division du vide de PIAB en 1968, après avoir inventé la première pompe à vide du monde, basée sur la technologie de l’éjecteur multi-étage. Depuis, PIAB a continué à faire la course en tête dans le développement de la technologie, avec l’invention de la technologie COAX® par exemple — Un système de vide utilisant la technologie COAX® peut augmenter la vitesse des processus d’automatisation industrielle jusqu’à 40%, peut produire trois fois plus de circulation de vide et consommer beaucoup moins d’air comprimé que les technologies de vide conventionnelles. ”La famille Tell a fait de PIAB une entreprise impressionnante, avec des produits phares de l’industrie. A partir de cette plateforme, nous prévoyons de mener une consolidation globale et de faire de PIAB un acteur important du secteur de l’automatisation industrielle” indique Harald Mix, Partenaire-associé chez Altor Equity Partners AB. PIAB AB Suède, producteur d’équipements de mesure de force, continuera à appartenir à la famille Tell, mais changera de nom pour s’appeler Xerex AB.
English to French: Combination Therapy for Hypertension in High-Risk Patients
Source text - English ENGLISH Copyright © 2009 Massachusetts Medical Society. All rights reserved. ESTABLISHED IN 1812 DECEMBER 4, 2008 VOL. 359 NO. 23 Combination Therapy for Hypertension in High-Risk Patients Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients Kenneth Jamerson, M.D., Michael A. Weber, M.D., George L. Bakris, M.D., Björn Dahlöf, M.D., Bertram Pitt, M.D., Victor Shi, M.D., Allen Hester, Ph.D., Jitendra Gupte, M.S., Marjorie Gatlin, M.D., and Eric J. Velazquez, M.D., for the ACCOMPLISH trial investigators* Abstract From the University of Michigan Health System, Ann Arbor (K.J., B.P.); the State University of New York Downstate Medical College, Brooklyn (M.A.W.); the University of Chicago Pritzker School of Medicine, Chicago (G.L.B.); Sahlgrenska University Hospital, Gothenburg, Sweden (B.D.); Novartis Pharmaceuticals, East Hanover, NJ (V.S., A.H., J.G., M.G.); and Duke University School of Medicine, Durham, NC (E.J.V.). Address reprint requests to Dr. Jamerson at the Division of Cardiovascular Medicine, University of Michigan Health System, 24 Frank Lloyd Wright Dr., Lobby M, Ann Arbor, MI 48106, or at [email protected]. *The investigators participating in the Avoiding Cardiovascular Events through Combination Therapy in Patients Liv-ing with Systolic Hypertension (ACCOMPLISH) trial are listed in the Appendix. N Engl J Med 2008;359:2417-28. Copyright © 2008 Massachusetts Medical Society. Background The optimal combination drug therapy for hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic. We hypothesized that treatment with the combination of an angiotensin-converting–enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reducing the rate of cardiovascular events than treatment with an ACE inhibitor plus a thiazide diuretic. Methods In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The primary end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization. Results The baseline characteristics of the two groups were similar. The trial was terminated early after a mean follow-up of 36 months, when the boundary of the prespecified stopping rule was exceeded. Mean blood pressures after dose adjustment were 131.6/73.3 mm Hg in the benazepril–amlodipine group and 132.5/74.4 mm Hg in the benazepril–hydrochlorothiazide group. There were 552 primary-outcome events in the benazepril–amlodipine group (9.6%) and 679 in the benazepril–hydrochlorothiazide group (11.8%), representing an absolute risk reduction with benazepril–amlodipine therapy of 2.2% and a relative risk reduction of 19.6% (hazard ratio, 0.80, 95% confidence interval [CI], 0.72 to 0.90; P	Translation - French FRENCH/EUROPE Copyright © 2009 Massachusetts Medical Society. Tous droits réservés. FONDÉ EN 1812 DECEMBRE 4, 2008 VOL. 359 N°. 23 Association thérapeutique contre l’hypertension artérielle des patients à haut risque L’association bénazépril-amlodipine ou bénazépril-hydrochlorothiazide dans l’hypertension artérielle des patients à haut risque Kenneth Jamerson, M.D., Michael A. Weber, M.D., George L. Bakris, M.D., Björn Dahlöf, M.D., Bertram Pitt, M.D., Victor Shi, M.D., Allen Hester, Ph.D., Jitendra Gupte, M.S., Marjorie Gatlin, M.D., and Eric J. Velazquez, M.D., investigateurs* de l’essai clinique ACCOMPLISH Résumé Ont participé : the University of Michigan Health System, Ann Arbor (K.J., B.P.), the State University of New York Downstate Medical College, Brooklyn (M.A.W.), the University of Chicago Pritzker School of Medicine, Chicago (G.L.B.), Sahlgrenska University Hospital, Gothenburg, Sweden (B.D.), Novartis Pharmaceuticals, East Hanover, NJ (V.S., A.H., J.G., M.G.) et Duke University School of Medicine, Durham, NC (E.J.V.). Adresser les demandes de tirés à part au Dr. Jamerson, Division of Cardiovascular Medicine, University of Michigan Health System, 24 Frank Lloyd Wright Dr., Lobby M, Ann Arbor, MI 48106, ou à [email protected]. *Les investigateurs ayant participé à l’essai ACCOMPLISH visant à éviter grâce à une association thérapeutique les événements cardiovasculaires des patients présentant une HTA systolique, sont énumérés en annexe. N Engl J Med 2008;359:2417-28. Copyright © 2008 Massachusetts Medical Society. Position du problème L’association optimale pour traiter l’hypertension artérielle n’est pas encore établie, bien que les directives actuellement en vigueur aux Etats-Unis préconisent le recours à un diurétique. Nous avons fait l’hypothèse qu’un traitement associant un inhibiteur de l’enzyme de conversion de l’angiotensine (ECA) à un inhibiteur des canaux calciques appartenant à la classe des dihydropyridines, serait plus efficace que l’association d’un inhibiteur de l’ECA et d’un diurétique thiazidique, pour réduire la fréquence des événements cardiovasculaires. Méthodes Dans un essai clinique randomisé en double aveugle, nous avons assigné11.506 patients hypertendus à haut risque d’événements cardiovasculaires, soit à l’association bénazépril-amlodipine, soit à l’association bénazépril-hydrochlorothiazide. Le critère principal était un mixte ou composite des morts d’origine cardiovasculaire, des infarctus du myocarde (IDM) non mortels, des accidents vasculaires cérébraux (AVC) non mortels, des hospitalisations pour angor, des réanimations après arrêt cardiaque subit et des revascularisations coronaires. Résultats Les caractéristiques de départ des deux groupes étaient similaires. L’essai s’est terminé précocement après un suivi moyen de 36 mois, lorsque le seuil fixé par la règle d’arrêt préspécifiée a été dépassé. Les pressions artérielles (PA) moyennes après ajustement des doses furent de 131,6/73,3 mm Hg dans le groupe bénazépril-amlodipine et de 132,5/74,4 mm Hg dans le groupe bénazépril-hydrochlorothiazide. Il y eut 552 événements répondant au critère principal dans le groupe bénazépril–amlodipine (9,6 %) et 679 dans le groupe benazepril–hydrochlorothiazide (11,8 %), représentant pour le traitement par benazepril–amlodipine une diminution du risque absolu de 2,2 % et une diminution du risque relatif de 19,6 % (hazard ratio de 0,80, avec un intervalle de confiance [IC] à 95 % : 0,72 à 0,90 ; P
English to French: Study synopsis General field: Medical Detailed field: Medical: Health Care
Source text - English Study Design & Methodology This is an open-label, multi-centre, uncontrolled clinical study for subjects with heparin induced thrombocytopenia Type II who require parenteral antithrombotic therapy. Patients will be assessed from baseline, during treatment and 24h after the end of infusion, with a follow-up observation at 30 days after the end of the treatment, or hospital discharge whichever is earlier. When hospital discharge is earlier, patients will be contacted by telephone to make a clinical outcome assessment at 30 days after end of treatment. The study will comprise one pre-study examination within 3 days prior (argatroban will be given at the time of HIT type II diagnosis) to the post-treatment period. Patients will be hospitalised during the period of anticoagulation with argatroban. An Independent Scientific Committee will review enrolment at 6 months after the start of recruitment or when recruitment is 50% complete, whichever is earlier, and will make recommendations based on study logistics and safety to either continue, amend or stop the study.	Translation - French Schéma de l’étude & Méthodologie Il s’agit d’une étude clinique ouverte non contrôlée et multicentrique, portant sur des sujets atteints d’une TIH de type II, nécessitant un traitement antithrombotique parentéral. Les patient seront évalués par rapport à un bilan de départ, pendant toute la durée du traitement et 24 heures après l’arrêt de la perfusion, avec un examen de suivi 30 jours après la fin du traitement ou à la sortie de l’hôpital, en optant pour l’éventualité la plus précoce. Si la sortie de l’hôpital intervient en premier, les patients seront contactés par téléphone pour faire une évaluation des résultats 30 jours après la fin du traitement. L’étude comportera un examen précédant la période post-thérapeutique ; il sera fait dans les 3 jours qui la précéderont (l’argatroban étant administré à partir du moment où le diagnostic de TIH de type II est porté). Les patients seront hospitalisés durant la période d’anticoagulation par argatroban. Un Comité scientifique indépendant supervisera les recrutements 6 mois après leur début ou lorsque ces derniers seront réalisés à 50 %, en optant pour l’éventualité la plus précoce. Le Comité fera des recommandations basées sur la logistique de l’étude et sa sécurité, en vue de continuer, modifier ou arrêter l’étude.

Master's degree - MD - Paris University

Years of experience: 22. Registered at ProZ.com: Jun 2003.

N/A

English to French (7. ProZ Certified PRO EN-FR)

French Multidisciplinary Academy of sciences

Adobe Acrobat, Microsoft Excel, Microsoft Word, Adobie standard, Excel, Powerpoint

CV available upon request

François Begon endorses ProZ.com's Professional Guidelines (v1.1).

Meet new translation company clients
Screen new clients (risk management)
Network with other language professionals
Get help with terminology and resources
Get help on technical issues / improve my technical skills
Learn more about additional services I can provide my clients
Stay up to date on what is happening in the language industry
Help or teach others with what I have learned over the years
Transition from freelancer to agency owner

Bio

RESUME & CV OF FRANÇOIS BEGON
MD, MSc. and Full professor of medicine

Address: François P. Begon
74, rue de la Colonie, F-75013 PARIS (France)
Tel: +33 (0)1 45 88 47 02
Fax/Tel: +33 (0)5 6169 99 27
Mobile phone: +33 (0)6 84 96 57 92
Emails:
[email protected]
[email protected]

PRESENTATION:
1. English - French Translator as Freelance since 2003 (12 years)
2. Editor & Proof-reader (Specialized); Subject Matter Expert
3. Linguistic QA, Proofing & DTP
4. MD and MSc.
6. Full Professor of medicine at Poitiers’ University - France
7. Member of the French Multidisciplinary Academy of Sciences
8. ProZ.com Certified PRO in English to French
9. Number of Jobs per Year: 160 in 2014 including 52% Edits, 48% Translations
10. Proofreading: Checking the understanding, style, localisation, grammar, spelling,
abbreviations & acronyms; Double reading: “fair copy” (Track Changes) and “clean” version.
11. Availability: 7/7

12. MEDICINE:
a) Internal Medicine, Oncology (clinical trials), Cardiology, Diabetes, Aids, Gastroenterology, Hepatology, Immunology, Nephrology (haemodialysis, grafts), Urology, Haematology, Infectious disease, Endocrinology, Neurology, Psychiatry, Psychology
b) Pharmaceuticals, Clinical Trials
c) Medical instruments, Medical Devices, Prostheses & Equipments
d) Medical Advertising & Marketing
e) Imaging, Nuclear Medicine
f) Biology: Biochemistry, Molecular Biology, Immunology, Clinical Labs, Biotech
g) Aesthetic medicine

15. WORKING WITH 157 Agencies and 416 Companies or Institutions
16. Ex-Editor in chief of an international Journal, Taylor & Francis Ltd, London
17. Pair: English > French
18. Team work: with a colleague PhD in Biology and Pharmaceuticals (reviewing)
19. Native Language: French
20. Number of years experience: 13
21. Rates:
Translation: US $ 0.10/source word; Euros € 0.085/source word
Proofreading/Editing: US $ 0.035/English Word (1 K words/hour) and 35.00 US$/Hour
Euros €0.030 / English Word (1 K words/hour) and €30.00/Hour
22. Website: http://www.translatorscafe.com/cafe/member10195.htm &
http://www.proz.com/profile/54586
23. Number of words / day: 2,500 - 3,000
24. Software: MS office: Word, Excel, PowerPoint; Adobe Standard 8.0, ScanSoft PDF Converter

25. ACADEMIC BACKGOUND:
 M.Sc.: Biochemistry, Cellular Biology, Physiology, Biophysics, Physics, Nuclear
 MD with honours - Silver Medal - Paris’ Faculty of Medicine
 Molecular Biology Graduate Studies
 Statistics Graduate: Methodology, Medicine, Biology, Epidemiology, Clinical trials
 Nuclear Physics Graduate Studies: National Institute for Nuclear Sciences and Techniques
 Full Professor at University Medical School (Poitiers)
 Member of the French Multidisciplinary Academy of Sciences

26.0 EXPERIENCE & REFERENCES as Translator & Proof-Reader / Editor:
 Ex Editor in chief of an International Journal, Taylor & Francis Ltd, London
 Eng>Fr Translator & Proofreader since 2003
 ProZ.com Certified PRO into English to French
 Working with 157 Agencies and 416 Companies & Institutions

27. REFERENCE AGENCIES:
▪CRAFT TRANSLATION (USA))
M Jeff Nuuner
Email: [email protected]
Tel. 01 646 865 2000

▪CORPORATE TRANSLATION Inc. (USA)
L Morgan
Email: [email protected]
Tel: 01 860-727-6026

▪ MAGPIE Språkproduktion AB (Sweden)
M. Patrick
[email protected]
Tel: +46 8 6522705

28. LATEST JOB SAMPLES
87 Jobs including 49 translations & 38 Edits
• Edit: Saline filled Breast Implant
• Translation: PARP Inhibitors
• Translation: Cardiac Rehabilitation programmes
• Edit: Phase III Study of a mab in Patients with Advanced Renal Cell Carcinoma
• Edit: Topical Skin Adhesive
• Translation: Plant Master File
• Edit: Antibiotics and Myelosuppression
• Edit: IFU of the Combination Pipéracillin + Tazobactam
• Edit: Protocol Synopsis Evaluating GS-5806 in Lung Transplant
• Translation: Improving safety and efficiency using a dose management
• Edit: Rotavirus, Information to parents
• Translation: BMS’ Transfer Pricing European Masterfile
• Edit: T2 Diabetes Mellitus Management
• Translation: Genetic testing of chromosome disease
• Translation: Mechanism of dissociation of Mind-Brain Complex
• Edit: Clinical Advance in Multiple sclerosis
• Translation: Fluorescent Processing Overview
• Translation: Treatment of attention deficit hyperactivity disorder (ADHD): Atomoxetine and
Synaptic reconstruction
• Edit: Dry Age-Related Macular Degeneration
• Edit: Intelligent Counter-pulsation
• Translation: Pirfenidone in Idiopathic Pulmonary Fibrosis
• Edit: Novel Therapies for Multiple Sclerosis
• Edit : Human Papillomavirus Vaccine [Types 16, 18]
• Edit: ICRC chronic osteomyelitis study
• Edit: Injuries to bones and joints
• Translation: Injuries of vertebral column and spinal cord
• Translation: Amputations and Disarticulations of limbs
• Edit: War Surgery - ICRC
• Edit: Explosions and Primary Blast Injuries
• Edit: PCS2 Plasma Collection System
• Edit: Type 2-Diabetes Research Study
• Edit: Product Information for Middle Ear Implants
• Edit: Injuries to Peripheral Nerves
• Translation: Bioactive Synthetic Graft
• Translation: Remodulin Messages (Marketing)
• Translation: Rheumatoid arthritis: Treatment with etanercept and methotrexate
• Translation: The Most Advanced Technique in ACL Reconstruction
• Edit: Acne Guidelines, Acne Treatment Algorithm
• Translation: Functional EndoSinusal Surgery FESS Instruments
• Edit: Post marketing adverse event reporting
• Translation: Trans-Oral Robotic Procedures (TORS) Pharyngo-Laryngoscope
• Translation: A New Test Strip Technology Platform for Self-Monitoring of Blood Glucose
• Translation: Mesh Implants
• Translation: Endoscopic Clip Applier
• Edit: Manikin-based life-saving, diagnosis and treatment
• Edit: Resorbable Haemostats
• Edit: Novartis & Sandoz’s Biopharmaceuticals & Biosimilars
• Translation: Auditory hallucinations and their mechanisms
• Translation: Summary of Product Characteristics of Droperidol
• Translation: Hypothesis on synaptic conversion mechanism following electroconvulsive
therapy
• Translation: Protection of subject privacy
• Translation: Patient types and treatment drivers in Follicular Lymphoma
• Translation: Inspection of Good clinical practices and Pharmacovigilance
• Edit: Adalimumab, Highlights on Prescribing Information
• Translation: Employee Performance Evaluation
• Edit: Drug-Resistant Gram-Negative Infections
• Translation: Heartburn/Gastroesophageal reflux disease (GORD)
• Translation: Market study on Ulcerative Colitis/Crohn’s Disease
• Edit: SmPC of the ACE-Inhibitor Ramipril from KRKA
• Edit: A Phase 3 Randomized Study to Evaluate the Efficacy and Safety of Lesinurad and
Febuxostat at Lowering Serum Uric Acid
• Edit: Study participation on AMG 162 Dénosumab
• Translation: Seniors and medications
• Translation: Epoietin Immunogenicity
• Translation: Insulin Biosimilars
• Translation: ACS Guideline-Based Decision-Making in NSTEMI
• Edit: Humira® (adalimumab) Pen
• Edit: Event of Special Interest: Blood Stream Infection Associated
• Translation: Are Mental Disorders a “Synapse Disease”?
• Translation: Diabetes and Heart
• Translation: Understanding Cold & Flu
• Translation: Allergy Awareness Programme
• Translation: Portable B-Mode Ultrasonic Scanner
• Edit: Blood glucose control in people with type 2 diabetes mellitus
• Translation: Percutaneous Transluminal Coronary Angioplasty
• Edit: Ionization Sterilisation
• Translation: Sirolimus Eluting Coronary Stent
• Translation: Brain Memory System
• Edit: IFU – Restylane Injector
• Translation: Cardiac and Respiratory Monitoring
• Translation: Mind and Matter; A theory of psychiatric monistic parallelism
• Translation : Stent-Graft System
• Translation: Proliferating cell nuclear antigen (PCNA)
• Translation: Multi Parameter Patient Monitor Operator’s Manual

free hit counter

This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.

Total pts earned: 2470 PRO-level pts: 2335
Language (PRO)
English to French	2335
Top general fields (PRO)
Medical	1179
Bus/Financial	581
Other	217
Tech/Engineering	132
Science	106
Pts in 3 more flds >
Top specific fields (PRO)
Medical (general)	691
Finance (general)	475
Medical: Pharmaceuticals	340
Medical: Health Care	159
Medical: Instruments	128
Human Resources	90
Biology (-tech,-chem,micro-)	86
Pts in 17 more flds >
See all points earned >

Keywords: Professor of medicine, MD, Medicine, Medical, English to French, Translation, Translator, Freelance, Editing, Proofreading. See more.Professor of medicine, MD, Medicine, Medical, English to French, Translation, Translator, Freelance, Editing, Proofreading, Review, subject matter expert, Freelancer, Pharmaceuticals, Cardiology, Oncology, Diabetes, Gastroenterology, Nephrology, Haematology, Immunology, AIDS, Endocrinology, Infectious disease, Neurology, Urology, Psychiatry, Aesthetic, Health care, Health, Trials, Medical Instruments, Medical Devices, Prostheses, Imaging, Clinical Lab, Biotech, Biochemistry, Molecular Biology, Statistics, Advertising, Marketing, Environment, Biology, Device, Instrument, prosthesis, Safety, Lab. See less.

This profile has received 79 visits in the last month,
from a total of 46 visitors

Profile last updated
Jul 9, 2019

More translators and interpreters: English to French More language pairs

Your current localization setting

Select a language

You have native languages that can be verified

Your current localization setting

Select a language